All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Incorporating thyroid markers in Down syndrome screening protocols

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F27661989%3A_____%2F17%3AN0000006" target="_blank" >RIV/27661989:_____/17:N0000006 - isvavai.cz</a>

  • Result on the web

    <a href="https://obgyn.onlinelibrary.wiley.com/doi/10.1002/pd.5047" target="_blank" >https://obgyn.onlinelibrary.wiley.com/doi/10.1002/pd.5047</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1002/pd.5047" target="_blank" >10.1002/pd.5047</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Incorporating thyroid markers in Down syndrome screening protocols

  • Original language description

    ObjectiveThe article aimed to assess the benefit of incorporating maternal serum thyroid disease marker levels (thyroid-stimulating hormone and free thyroxine) into first trimester Down syndrome screening protocols. MethodsStatistical modelling was used to predict performance with and without the thyroid markers. Two protocols were considered: the combined test and the contingent cell-free DNA (cfDNA) test, where 15-40% women are selected for cfDNA because of increased risk based on combined test results. Published parameters were used for the combined test, cfDNA and the Down syndrome means for thyroid-stimulating hormone and free thyroxine; other parameters were derived from a series of 5230 women screened for both thyroid disease and Down syndrome. ResultsCombined test: For a fixed 85% detection rate, the predicted false positive rate was reduced from 5.3% to 3.6% with the addition of the thyroid markers. Contingent cfDNA test: For a fixed 95% detection rate, the proportion of women selected for cfDNA was reduced from 25.6% to 20.2%. ConclusionsWhen screening simultaneously for maternal thyroid disease and Down syndrome, thyroid marker levels should be used in the calculation of Down syndrome risk. The benefit is modest but can be achieved with no additional cost. (c) 2017 John Wiley & Sons, Ltd.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30200 - Clinical medicine

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2017

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Prenatal Diagnosis

  • ISSN

    0197-3851

  • e-ISSN

    1097-0223

  • Volume of the periodical

    37

  • Issue of the periodical within the volume

    5

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    5

  • Pages from-to

    510-514

  • UT code for WoS article

    000401561200013

  • EID of the result in the Scopus database

    2-s2.0-85018935336